Holen Sie sich die Stockscreener-App
5.83
4.95%
0.275
Schlusskurs vom Vortag:
$5.555
Offen:
$5.67
24-Stunden-Volumen:
3.80M
Relative Volume:
1.38
Marktkapitalisierung:
$518.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-2.67%
1M Leistung:
+14.09%
6M Leistung:
+62.40%
1J Leistung:
+161.43%
1-Tages-Spanne:
$5.4587
$5.90
1-Wochen-Bereich:
$5.15
$6.905
52-Wochen-Spanne:
$1.67
$6.905
Atyr Pharma Inc Stock (ATYR) Company Profile
Firmenname
Atyr Pharma Inc
Sektor
Branche
Telefon
(858) 731-8389
Adresse
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Vergleichen Sie ATYR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
5.83 | 494.42M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-18 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-04 | Eingeleitet | Wells Fargo | Overweight |
| 2024-09-05 | Eingeleitet | Jefferies | Buy |
| 2023-07-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-10-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-09-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-10 | Eingeleitet | Laidlaw | Buy |
| 2020-08-17 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-12-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2015-12-16 | Eingeleitet | Citigroup | Neutral |
| 2015-06-01 | Eingeleitet | Citigroup | Buy |
| 2015-06-01 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Atyr Pharma Inc Aktie (ATYR) Neueste Nachrichten
Does aTyr Pharma Inc. stock pay reliable dividendsHigh-performance investment picks - jammulinksnews.com
RNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP TherapeuticsResearchAndMarkets.com - FinancialContent
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga
aTyr Pharma Soars 11.26% on Phase 3 Study Completion - AInvest
aTyr Pharma stock holds Buy rating as Phase 3 trial completes - Investing.com Canada
Is aTyr Pharma Inc. a good long term investmentRecord-breaking gains - Autocar Professional
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout - TipRanks
What analysts say about aTyr Pharma Inc. stockMarket-leading capital gains - Autocar Professional
aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire
What drives aTyr Pharma Inc. stock priceMarket-beating returns - jammulinksnews.com
aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com
aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study - TipRanks
First-Ever Global Phase 3 Trial for Sarcoidosis Treatment Reaches Major Milestone with 268 Patients - Stock Titan
aTyr Pharma Reaches US$515m Market Cap Benefiting Insider Stock Buying - simplywall.st
aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding - GlobeNewswire Inc.
What makes aTyr Pharma Inc. stock price move sharplyFree Stock Trading Community - beatles.ru
How aTyr Pharma Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser
Why aTyr Pharma Inc. stock attracts strong analyst attentionProven Win Setups - Newser
Can ATyr's EFZO-FIT Data Help Patients And Investors Breathe Easier? - RTTNews
Pulmonary Sarcoidosis Market on Track for Major Expansion - openPR.com
Pulmonary Sarcoidosis Market on Track for Major Expansion by 2032, According to DelveInsight | aTyr Pharma, Kinevant Sciences, Novartis, aTyr Pharma, Novartis Pharma, Mallinckrodt - Barchart.com
Favourable Signals For aTyr Pharma: Numerous Insiders Acquired Stock - Yahoo Finance
Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying - MSN
ATyr Pharma, Inc.(NasdaqCM: ATYR) added to Russell Small Cap Comp Value Index - MarketScreener
ATyr Pharma, Inc.(NasdaqCM: ATYR) added to Russell 3000E Value Index - MarketScreener
Leerink Partners Sticks to Its Buy Rating for aTyr Pharma (ATYR) - The Globe and Mail
aTyr Pharma to join Russell 2000 and 3000 indexes By Investing.com - Investing.com India
Finanzdaten der Atyr Pharma Inc-Aktie (ATYR)
Es liegen keine Finanzdaten für Atyr Pharma Inc (ATYR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):